Tissue-Specific Vulnerability to Apoptosis in Machado-Joseph Disease

Cells. 2023 May 17;12(10):1404. doi: 10.3390/cells12101404.

Abstract

Machado-Joseph disease (MJD) is a dominant neurodegenerative disease caused by an expanded CAG repeat in the ATXN3 gene encoding the ataxin-3 protein. Several cellular processes, including transcription and apoptosis, are disrupted in MJD. To gain further insights into the extent of dysregulation of mitochondrial apoptosis in MJD and to evaluate if expression alterations of specific apoptosis genes/proteins can be used as transcriptional biomarkers of disease, the expression levels of BCL2, BAX and TP53 and the BCL2/BAX ratio (an indicator of susceptibility to apoptosis) were assessed in blood and post-mortem brain samples from MJD subjects and MJD transgenic mice and controls. While patients show reduced levels of blood BCL2 transcripts, this measurement displays low accuracy to discriminate patients from matched controls. However, increased levels of blood BAX transcripts and decreased BCL2/BAX ratio are associated with earlier onset of disease, indicating a possible association with MJD pathogenesis. Post-mortem MJD brains show increased BCL2/BAX transcript ratio in the dentate cerebellar nucleus (DCN) and increased BCL2/BAX insoluble protein ratio in the DCN and pons, suggesting that in these regions, severely affected by degeneration in MJD, cells show signs of apoptosis resistance. Interestingly, a follow-up study of 18 patients further shows that blood BCL2 and TP53 transcript levels increase over time in MJD patients. Furthermore, while the similar levels of blood BCL2, BAX, and TP53 transcripts observed in preclinical subjects and controls is mimicked by pre-symptomatic MJD mice, the expression profile of these genes in patient brains is partially replicated by symptomatic MJD mice. Globally, our findings indicate that there is tissue-specific vulnerability to apoptosis in MJD subjects and that this tissue-dependent behavior is partially replicated in a MJD mouse model.

Keywords: ATXN3; MJD; SCA3; ataxin-3; biomarkers; human brains; mitochondrial apoptosis; polyglutamine disease; spinocerebellar ataxia type 3; transgenic mice.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis
  • Follow-Up Studies
  • Machado-Joseph Disease* / genetics
  • Machado-Joseph Disease* / metabolism
  • Machado-Joseph Disease* / pathology
  • Mice
  • Mice, Transgenic
  • Neurodegenerative Diseases* / complications
  • bcl-2-Associated X Protein / genetics

Substances

  • bcl-2-Associated X Protein

Grants and funding

This work was funded by FEDER funds through the Operational Competitiveness Program (COMPETE) and by National Funds through Fundação para a Ciência e a Tecnologia (FCT) under the project FCOMP-01-0124-FEDER-028753 (PTDC/DTP/PIC/0370/2012) and was also funded by National Ataxia Foundation through a research seed money grant (2018). A.F.F. was supported by PhD grant (SFRH/BD/121101/2016) funded by FCT, República Portuguesa/Ciência, Tecnologia e Ensino Superior, Portugal 2020, União Europeia/Fundo Social Europeu and POR_NORTE. MR is supported by FCT (CEECIND/03018/2018). M.d.C.C. was supported by the Heeringa Ataxia Research fund (University of Michigan). M.d.F.B. research was partially supported by National Funds through FCT—Fundação para a Ciência e Tecnologia, project UIDB/00006/2020 (CEAUL).